Autism diagnosis business SynapDx gains $15.4m Google-led financing


brain_lrgGoogle Ventures has led a $15.4m financing round for brain development disorder diagnosis business SynapDx Corporation.

Foundation Medical Partners also joined the round as a new investor alongside existing backers North Bridge Venture Partners and General Catalyst Partners.

The company is currently developing what would be a breakthrough blood-based autism spectrum disorder test designed to help earlier identification of children with autism.

Andrew Conrad from Google has joined the SynapDx’s board of directors following the funding round.

Google Ventures general partner Krishna Yeshwant said, “SynapDx’s use of advanced technologies and multiple analytes to generate the most informative blood test possible is a great example of the type of industry-altering innovation we look for at Google Ventures.

“Andy and I look forward to focusing on this important mission and accelerating the company’s growth.”

Last August US private equity firm Adams Street Partners  led a $1.75m seed funding round for MyHealthTeams, which has created condition-specific social networks for people with chronic health conditions including autism.

MyHealthTeams’ fast-growing flagship site MyAutismTeam serves the needs of parents of children with autism.

After privately launching in June 2011 with 30 parents in San Francisco, it quickly grew to more than 26,000 registered parents from all across the country.

The company is following the same strategy for other chronic conditions and diseases.

Copyright © 2013 AltAssets